Collecting Tumor Samples From Patients With Gynecological Tumors
Collecting Tumor Samples From Patients With Gynecological Tumors
This laboratory study is collecting tumor tissue and blood samples from patients with
 gynecologic tumors. Collecting and storing samples of tumor tissue and blood from patients
 with cancer to study in the laboratory may help in the study of cancer.
PRIMARY OBJECTIVES:

 I. To collect gynecologic tissue and blood from participating Gynecologic Oncology Group
 (GOG) institutions.

 II. To provide a repository for long-term storage of gynecologic tissue and blood that will
 be used in studies designed to better understand the molecular biology of gynecologic tumors.

 III. To make available, through the GOG Tissue Bank, tissue and blood for proposed projects
 conducted by GOG and non-GOG investigators.

 OUTLINE:

 Snap frozen tumor tissue, OCT molds of tumor tissue, formalin-preserved tumor tissue, buffy
 coat-prepared tumor tissue, and blood samples are collected and stored in the repository.
 Patient information is kept confidential, and patients are not informed of any research/test
 results from use of their tissues.
Inclusion Criteria:

 -  Any of the following:

 -  Patients who have had gynecologic tissue removed during surgery to diagnosis,
 treat, monitor, and/or prevent primary, persistent, or recurrent gynecologic
 cancer of the ovary, peritoneum, fallopian tube, cervix, uterine corpus, vagina,
 or vulva, meeting at least one of the following criteria:

 -  Group A: Women who underwent surgery, were diagnosed with a primary
 gynecologic malignancy of the ovary, cervix, uterine corpus, or vulva, and
 have primary tumor, normal tissue, and blood available for submission for
 this protocol

 -  Patients with ovarian cancer including all stages, grades, and common
 epithelial cell types

 -  Invasive cancers and serous and mucinous borderline tumors of low
 malignant potential are allowed

 -  At least 1 gram of frozen primary tumor tissue must be submitted
 for this protocol for patients with FIGO stage III or IV
 epithelial ovarian cancer

 -  Patients with an invasive malignancy of the cervix or uterine corpus
 including all stages, grades, and common cell types

 -  Patients with squamous cell carcinoma of the vulva

 -  Group B: Women who underwent surgery and were diagnosed with a rare
 gynecologic malignancy of the ovary, peritoneum, fallopian tube, cervix,
 uterine corpus, vagina, vulva, a gestational trophoblastic tumor, or a tumor
 arising in endometriosis, and have tumor tissue available for submission for
 this protocol

 -  Patients with a rare gynecologic malignancy of the ovary including
 malignant germ cell tumors; sex cord-stromal tumors; malignant mixed
 mesodermal tumors; clear cell, mucinous, small cell, or transitional
 cell carcinomas; malignant Brenner tumors; or borderline tumors of low
 malignant potential (except serous and mucinous)

 -  Patients with a rare gynecologic malignancy of the peritoneum,
 including primary peritoneal cancer or mesothelioma

 -  Patients with carcinoma of the fallopian tube

 -  Patients with a rare gynecologic malignancy of the cervix including
 verrucous, small cell, clear cell, serous, or adenoid cystic
 carcinomas; carcinoid tumors; malignant mixed mesodermal tumors; or
 leiomyosarcoma

 -  Patients with a rare gynecologic malignancy of the uterine corpus
 including leiomyosarcoma; malignant mixed mesodermal tumors;
 endometrial stromal sarcomas; smooth muscle tumors of unknown malignant
 potential; or clear cell or small cell carcinomas

 -  Patients with a rare gynecologic malignancy of the vagina including
 verrucous or clear cell carcinomas; melanoma; embryonal
 rhabdomyosarcoma; or endodermal sinus tumor

 -  Patients with a rare gynecologic malignancy of the vulva including
 verrucous carcinoma; melanoma; aggressive angiomyxoma; sarcoma;
 malignant Paget's disease; or Bartholin gland carcinoma

 -  Patients with a gestational trophoblastic tumor

 -  Patients with a tumor arising in endometriosis

 -  Group C: Women who underwent prophylactic oophorectomy and have at least 1
 gram of ovarian tissue and blood available for submission for this protocol

 -  Group D: Women who underwent surgery to monitor or treat a persistent or
 recurrent gynecologic malignancy of the ovary, peritoneum, fallopian tube,
 cervix, uterine corpus, vagina, or vulva, and have persistent or recurrent
 tumor, normal tissue, and blood available for submission for this protocol

 -  Concurrent primary cancers are allowed

 -  No benign cystic tumors of the ovary, including cystic epithelial tumors and mature
 cystic teratomas

 -  Prior cytotoxic chemotherapy allowed

 -  Prior hormonal therapy allowed

 -  Prior radiotherapy allowed

 -  Prior surgery allowed

 -  No more than 6 weeks after prior surgery